The compound will be investigated for nonalcoholic steatohepatitis. RNAi destroys messenger RNA made from genes, which can prevent the creation of disease-causing proteins, Dicerna said. The company's GalXC technology consists of an N-acetyl-D-galactosamine (GalNAc) structure of double-stranded RNA molecules that bind to liver cell receptors.

Dicerna will receive a preclinical milestone payment from Boehringer Ingelheim for the compound, called DCR-LIV2, which it expects to receive in the second quarter of this year. Dicerna is eligible to receive up to $170 million in additional milestone payments, as well as royalties on potential global net sales.

Oxford Biomedica to manufacture vectors for Boehringer Ingelheim
Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.

Boehringer Ingelheim, Cure Genetics to develop novel AAV
Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp...

FDA issues IND application to Dicerna, Lilly for RNAi candidate
Dicerna Pharmaceuticals' investigational new drug (IND) application for LY3561774, an RNA interference (RNAi) therapeutic, has been accepted by the U.S....

Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies
Boehringer Ingelheim and Oxford BioTherapeutics are partnering to discover novel targets for cancer immunotherapies using the Oxford Genome Anatomy Project's...

Boehringer Ingelheim acquires Northern Biologics
Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.